- HYTN (HYTN) has announced the launch of cannabis products in Australia
- The products being formulated and manufactured for Promethean are selling under the Australian Therapeutic Goods Administration (TGA) Special Access and Authorized Prescriber Scheme
- The products are cannabis oil in water emulsions featuring HYTN’s Elevation Technology®
- They are also packaged in 60mL bottles each containing 1,200 mg of cannabinoids
- HYTN Innovations Inc. (HYTN) is down 2.78 per cent, trading at C$0.35 at 9:37 am EST
HYTN Innovations (HYTN) has introduced cannabis nano-emulsions featuring HYTN’s proprietary Elevation Technology to the Australian medical cannabis market.
The products being formulated and manufactured through an agreement with Promethean BioPharma are selling under the Australian Therapeutic Goods Administration (TGA) Special Access and Authorized Prescriber Scheme.
The products are cannabis oil in water emulsions featuring HYTN’s Elevation Technology and include a high CBD product, a balanced CBD: THC product, a high THC product and a CBD isolate product.
The products, which HYTN believes are the first of their kind to reach the Australian market, are packaged in 60mL bottles each containing 1,200 mg of cannabinoids.
Jason Broome, HYTN Chief Operating Officer, stated,
“Delivering cannabinoids orally has traditionally been a challenge. Oil-in-oil formulations, whereby cannabis distillate or isolate is suspended in an oil such as medium-chain triglycerides (MCTs), tend to have diminished bioavailability and onset times, resulting in reduced efficacy.”
“Newer stable nano-emulsions such as those featuring our Elevation Technology® have an average particle size of <100 nm, which enhances both bioavailability and onset times,” added Jason Broome.
“The first of the Products have been prescribed in Sydney and are being distributed across Australia,” stated Peter Comerford, Promethean Chief Executive Officer.
HYTN, as stated in its business plan, intends to continue to explore opportunities to expand its product capabilities in emerging legal cannabis markets. It hopes this will be the first of many projects highlighting its Elevation Technology® for medical purposes.
HYTN formulates, manufactures, markets, and sells premium cannabis goods.
With the mission to be the leading provider of consistent, natural, and delicious cannabis products, HYTN focuses its efforts on identifying category opportunities and takes an innovative approach to deliver elevated cannabis experiences to a discerning customer base.
HYTN Innovations Inc. (HYTN) is down 2.78 per cent, trading at C$0.35 at 9:37 am EST.
